Myers Scott Dunseth
SEC insider (Form 3/4/5 filer). CIK 0001356256. Director at Zentalis Pharmaceuticals, Inc. (ZNTL) and 1 other issuer. 8 reported Form 4/5 transactions since Sep 2024; latest on Jun 16, 2026. Located in SAN DIEGO, CA.
Companies Myers Scott Dunseth has filed insider reports for
- Zentalis Pharmaceuticals, Inc. (ZNTL): Director
- DYNAVAX TECHNOLOGIES CORP (DVAX): Director
Myers Scott Dunseth
CIK: 0001356256
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Jun 16, 2026ZNTL
Zentalis Pharmaceuticals, Inc.
AwardDirect57.1K shares- - Feb 10, 2026DVAX
DYNAVAX TECHNOLOGIES CORP
Tender OfferDirect3.8K shares- - Feb 10, 2026DVAX
DYNAVAX TECHNOLOGIES CORP
DispositionDirect31.2K shares- - Aug 22, 2025DVAX
DYNAVAX TECHNOLOGIES CORP
PurchaseDirect3.8K shares at avg. $10.82$41K - Jun 17, 2025ZNTL
Zentalis Pharmaceuticals, Inc.
AwardDirect57.6K shares- - Jun 11, 2025DVAX
DYNAVAX TECHNOLOGIES CORP
AwardDirect5.8K shares- - Apr 30, 2025ZNTL
Zentalis Pharmaceuticals, Inc.
PurchaseDirect21K shares at avg. $1.40$29K - Nov 13, 2024ZNTL
Zentalis Pharmaceuticals, Inc.
AwardDirect260.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 16, 2026 |  ZNTL Zentalis Pharmaceuticals, Inc. | Award | 57,100 | - | $0 | Direct |
| Feb 10, 2026 |  DVAX DYNAVAX TECHNOLOGIES CORP | Tender Offer | 3,800 | - | $0 | Direct |
| Feb 10, 2026 | DVAX DYNAVAX TECHNOLOGIES CORP | Disposition | 31,204 | - | $0 | Direct |
| Aug 22, 2025 | DVAX DYNAVAX TECHNOLOGIES CORP | Purchase | 3,800 | $10.82 | $41,116 | Direct |
| Jun 17, 2025 | ZNTL Zentalis Pharmaceuticals, Inc. | Award | 57,603 | - | - | Direct |
| Jun 11, 2025 | DVAX DYNAVAX TECHNOLOGIES CORP | Award | 5,758 | - | - | Direct |
| Apr 30, 2025 | ZNTL Zentalis Pharmaceuticals, Inc. | Purchase | 21,000 | $1.40 | $29,373 | Direct |
| Nov 13, 2024 | ZNTL Zentalis Pharmaceuticals, Inc. | Award | 260,192 | - | $0 | Direct |
1-8 of 8 transactions